Stock Screener App

Frei -

Installieren

1.04

1.89% -0.02

after-market

Handel nachbörslich: 1.07 0.03 +2.88%

Cognition Therapeutics Inc (CGTX)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten

Cognition Therapeutics shifts focus to DLB psychosis treatment By Investing.com - Investing.com Australia

Cognition Therapeutics shifts focus to DLB psychosis treatment - Investing.com Nigeria

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - Bitget

Cognition Therapeutics Advances Zervimesine for DLB Psychosis - TipRanks

Cognition Therapeutics, Inc. Announces Advancement of Zervimesine Development for Dementia with Lewy Bodies Psychosis Treatment - Quiver Quantitative

Cognition Therapeutics advancing zervimesine (ct1812) for dementia with Lewy bodies (DLB) psychosis - marketscreener.com

Cognition Therapeutics advances zervimesine as registrational program for DLB psychosis after FDA Type C minutes - TradingView

Cognition Therapeutics Advancing Zervimesine (Ct1812) For Dementia With Lewy Bodies (DLB) Psychosis - TradingView

Zervimesine push: Cognition Therapeutics (NASDAQ: CGTX) targets DLB psychosis - Stock Titan

DLB psychosis often untreated — zervimesine study targets hallucinations - Stock Titan

CGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

COGNITION THERAPEUTICS, INC. (CGTX) Stock, Price, News, Quotes, Forecast and Insights - MSN

Can Cognition Therapeutics Inc disrupt its industryQuarterly Profit Report & Free Community Consensus Stock Picks - baoquankhu1.vn

Is Cognition Therapeutics Inc. stock a safe buy before earningsWeekly Trend Report & High Conviction Trade Alerts - mfd.ru

Whale Trades: Is Cognition Therapeutics Inc stock heavily shortedPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn

CGTX (CGTX) CFO reports tax-withholding share disposition on RSU vesting - Stock Titan

Cognition Therapeutics (CGTX) CEO RSU vesting leads to 5,850-share tax withholding - Stock Titan

Is Cognition Therapeutics Inc. stock overvalued by current metrics2025 Key Highlights & High Win Rate Trade Alerts - mfd.ru

Why Cognition Therapeutics Inc. stock is recommended by analysts2025 Market WrapUp & Reliable Volume Spike Alerts - mfd.ru

FY2025 Earnings Forecast for CGTX Issued By Brookline Cap M - Defense World

Cognition Therapeutics (NASDAQ:CGTX) Upgraded to Strong-Buy at Brookline Cap M - MarketBeat

Brookline Capital Management Predicts CGTX FY2025 Earnings - MarketBeat

Cognition Therapeutics (NASDAQ:CGTX) Upgraded at Brookline Capital Management - Defense World

Cognition Therapeutics extends expanded access program for Zervimesine (CT1812) in dementia with Lewy bodies - marketscreener.com

Cognition Therapeutics rises as it extends access to rare brain disorder drug - TradingView

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewswire

Cognition Therapeutics (NASDAQ:CGTX) Raised to "Strong-Buy" at Brookline Capital Management - MarketBeat

Cognition Therapeutics (NASDAQ:CGTX) Shares Up 4.6%Still a Buy? - MarketBeat

Cognition Therapeutics (NASDAQ:CGTX) Shares Up 4.6% – Still a Buy? - Defense World

Analyst Calls: Is Cognition Therapeutics Inc. stock a safe buy before earnings2025 Top Gainers & Precise Entry and Exit Recommendations - mfd.ru

Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug - Investing.com India

Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug By Investing.com - Investing.com Canada

Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial - TipRanks

Cognition Therapeutics Completes FDA Meeting for Zervimesine in DLB - TradingView

Cognition Therapeutics, Inc. Discusses Phase 2b Study Plans for Zervimesine in Dementia with Lewy Bodies During FDA Type C Meeting - Quiver Quantitative

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewswire

Street Watch: What is LCFYWs valuation compared to sectorTrade Risk Assessment & Stock Portfolio Risk Management - baoquankhu1.vn

Gainers Report: Whats next for Cognition Therapeutics Inc stockJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - baoquankhu1.vn

Published on: 2026-01-22 00:29:52 - baoquankhu1.vn

What is the PEG ratio of Cognition Therapeutics Inc.Analyst Downgrade & Capital Efficiency Focused Ideas - bollywoodhelpline.com

4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace

Market Catalysts: What is Cognition Therapeutics Incs debt to equity ratioInsider Selling & Capital Protection Trading Alerts - baoquankhu1.vn

Aug Catalysts: Whats the fair value of Cognition Therapeutics Inc stockPortfolio Value Summary & Real-Time Volume Spike Alerts - baoquankhu1.vn

Whats the fair value of Cognition Therapeutics Inc stock2025 Price Targets & Accurate Entry and Exit Point Alerts - baoquankhu1.vn

CEO Moves: Is Cognition Therapeutics Inc stock a top pick in earnings season2025 Risk Factors & Precise Trade Entry Recommendations - Bộ Nội Vụ

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Why Cognition Therapeutics Inc. stock could outperform in 2025Earnings Recap Report & High Yield Equity Trading Tips - Улправда

Trading Recap: Will Cognition Therapeutics Inc. stock outperform growth indexes2025 Analyst Calls & Community Consensus Trade Alerts - ulpravda.ru

How resilient is Cognition Therapeutics Inc. stock in market downturnsJuly 2025 Trade Ideas & Long-Term Investment Growth Plans - Улправда

Weekly Earnings: How Cognition Therapeutics Inc. stock reacts to oil pricesEarnings Performance Report & Stepwise Trade Signal Implementation - Улправда

Cognition Therapeutics, Inc.Common Stock (NQ: CGTX - FinancialContent

Cognition Therapeutics Announces Publication of Phase 2 Study Results for Zervimesine in Dementia with Lewy Bodies - Quiver Quantitative

Cognition Therapeutics Publishes Phase 2 Clinical Results - GlobeNewswire

Experimental Lewy body dementia drug eases symptoms in small trial - Stock Titan

DAVENPORT & Co LLC Makes New Investment in Cognition Therapeutics, Inc. $CGTX - MarketBeat

Earnings Risk: Why Cognition Therapeutics Inc stock could outperform in 2025Earnings Summary Report & Community Consensus Stock Picks - moha.gov.vn

How Cognition Therapeutics Inc. stock reacts to oil prices2025 Earnings Impact & Daily Technical Stock Forecast Reports - Улправда

Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB) - Wiley

[8-K] COGNITION THERAPEUTICS INC Reports Material Event | CGTX SEC FilingForm 8-K - Stock Titan

RPRX

$45.68

3.69%

MRNA

$53.83

6.87%

ROIV

$29.72

0.68%

BNTX

$101.95

1.78%

INSM

$143.54

4.23%

ONC

$292.94

2.03%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters